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Abstract
Background: High-risk human papillomaviruses (HPVs) are strongly associated with the development of some
malignancies. The E6 and E7 viral oncoproteins are the primary proteins responsible for cell homeostasis alteration
and immortalization. Furthermore, the E6 protein from high-risk HPVs can interact with the PDZ (PSD-90/Dlg/ZO-1)
domains of cellular proteins, triggering cell transformation. One protein that is associated with pathological conditions
and has a PDZ domain is the protease HTRA1 (high temperature requirement 1). This protein is poorly expressed
in some cancers, suggesting a tumor suppressor role. The aim of this study was to evaluate the effect of HTRA1
overexpression in HPV16-positive (CasKi) and HPV-negative (C33) cervical cell lines.
Methods: The cells were transfected with a vector containing the HTRA1 ORF or an empty vector. HTRA1
overexpression was confirmed by qRT-PCR. The cells were subjected to cell proliferation, colony formation,
apoptosis and cell cycle assays.
Results: C33 cells expressing HTRA1 grew significantly fewer colonies and showed less proliferation than cells
without HTRA1 expression. In contrast, in the CasKi cells overexpressing HTRA1, there was an increase in the cell
growth rate and in the colonies density compared to cells expressing low levels of HTRA1. An apoptosis assay
showed that HTRA1 does not interfere with the apoptosis rate in these cells. A cell cycle immunofluorescence
assay revealed more CasKi cells overexpressing HTRA1 in the S phase and more C33 HTRA1-transfected cells in
the G0/G1 phase, suggesting that HTRA1 plays different roles in the cell cycle progression of these cells.
Conclusions: HTRA1 overexpression prevents cell proliferation in the HPV-negative cell line and increases cell
proliferation in the HPV-positive cell line. Although the E6/HTRA1 interaction has already been described in the
literature, more studies are required to confirm whether the present functional findings are a result of this
interaction.
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Background
High-risk human papillomaviruses (HPVs) are DNA vi-
ruses strongly implicated in the development of some
malignances, such as cancer of the cervix (99 %) [1], anal
canal (80–85 %) [2], vulva (40 %) [3], vagina (~70 %) [3],
penis (~50 %) [4] and oropharynx (25 %) [5]. There are
over 200 types of HPVs identified [6], but the malignant
transformation of cervical epithelial cells is associated
with persistent high-risk HPV infections, such as HPV
16 and 18 [7]. HPV 16 is responsible for up to 50 % of
cervical cancers worldwide [8].
Cell pathways used by viral oncoproteins during viral
replication are frequently disrupted, contributing to the
development of HPV-associated cancers [9]. The E7
oncoprotein binds to the retinoblastome protein (pRb)
and targets it for degradation, resulting in the release
and activation of transcription factors (E2F) that drive S
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phase progression [10]. In the same way, the E6 oncopro-
tein binds to a cellular protein, E6-AP, and this complex
interacts with p53, resulting in the ubiquitin-dependent
degradation of the tumor suppressor p53 [11]. E6 is also
responsible for regulating the transcription of some genes,
for example, suppressing the expression of some tumor
suppressors [12–14]. The E6 carboxy-terminal region con-
served in high-risk HPVs is able to recognize and bind to
human proteins containing PDZ (PSD-90/Dlg/ZO-1) do-
mains, triggering their degradation, which increases E6
stability in infected cells [15, 16]. These cellular proteins
are localized at the interfaces of cell-cell contacts and form
signaling complexes that modulate cell growth, cell polar-
ity, and cell adhesion [16–19]. The E6/cellular protein in-
teractions are important to cancer progression induced by
the virus [20].
The HTRA1 (high temperature requirement 1) protein
is associated with several pathological conditions. This
protease has a PDZ domain and is encoded by a gene
located on chromosome 10 (10q26). Human HTRA1
belongs to a family of serine proteases involved in several
important biological functions, such as protein quality
control, cell growth, differentiation, apoptosis and degrad-
ation of extracellular matrix proteins [21, 22]. The HTRA1
protein contains an N-terminal regulatory domain, an
insulin-like growth factor binding protease (IGFBP) do-
main, a trypsin-like serine protease domain and a C-
terminal PDZ domain [23, 24]. The specific role of the
PDZ domain of HTRA1 is not clear; however, it is
known that PDZ recognizes C-terminal and internal
hydrophobic sequences of target proteins, regulating
HTRA1 protease activity [25, 26].
HTRA1 is involved in several pathologies [27–29] and
some types of cancer [30–36]. This protease is expressed
in several tissues, and transcription of its gene is highly
regulated in both developing and adult tissues [24].
HTRA1 expression is decreased in some cancers, such
as melanomas and lung and ovarian cancer, and the
reduction of cell proliferation after an increase of its
expression suggests a tumor suppressor role for this
protein [31, 32, 36]. HTRA1 transcript downregulation
was also observed in human keratinocytes immortalized
with HPV16 compared to normal keratinocytes [37].
Although HTRA1 has been shown to interact with the
E6 oncoprotein of high-risk HPVs, no studies have eval-
uated the role of HTRA1 in HPV-positive cells. Thus, in
the present study, we investigated HTRA1 protein func-
tion in HPV-positive and HPV-negative cell lines.
Methods
Cell lines
HPV-16 positive (CasKi) (ATCC: CRL-1550) and HPV-
negative (C33) (ATCC: HTB-31) human cervical carcin-
oma cell lines were grown in DMEM medium containing
10 % FBS (Fetal bovine serum) (Cultilab, SP, Brazil), sup-
plemented with 100 U/ml penicillin (Invitrogen, Grand Is-
land, NY, USA) and 100 μg/ml streptomycin (Invitrogen,
Grand Island, NY, USA) and were grown in a 37 °C, 5 %
CO2 atmosphere.
Plasmids and transfection
pCMV6/Entry and pCMV6/HTRA1 were obtained from
Origene Technologies (Origene Technologies, Rockville,
MD, USA). pCMV6 vectors contain the neomycin phos-
photransferase gene, which allows selection with a neo-
mycin analog such as G418 (Sigma-Aldrich, St. Louis,
MO, USA). The expression vectors were transfected into
cell lines using Fugene HD (Promega, Madison, WI, USA)
according to the manufacturer’s manual.
Colony formation assay and cell growth curves
Forty-eight hours after transfection with pCMV6 or
pCMV6/HTRA1, CasKi (9 × 104) and C33 (6 × 104) cells
were trypsinized and plated in 6-well plates in media
containing 800 μg/ml geneticin (G418, Sigma Aldrich, St
Louis, MO, USA). The cells continued to grow for
14 days with media changes every 2 days; colonies were
stained with 0.01 % crystal violet. Each experiment was
performed in triplicate and in two independent assays.
To determine the cell growth rate, CasKi and C33 cells
transfected and selected with G418 for 14 days were
plated in 24-well plates (CasKi 3 × 104 and C33 1 × 105
cells). After 24, 48 and 72 h, the cell number was counted
in a Neubauer Improved chamber.
Apoptosis assay
Apoptotic cells were analyzed using a FITC Annexin V
Apoptosis Detection Kit II (556570 - BD Biosciences,
San Diego, CA, USA) according to the manufacturer’s
instructions after they were transfected with pCMV6/
HTRA1 or empty vectors and subjected to 14 days of se-
lection with geneticin. The cells were washed with PBS
twice and then resuspended in binding buffer, and 5 μL
FITC-Annexin V and 5 μL Propidium Iodide (PI) were
added, after which the cells were incubated for 15 min
in the dark at room temperature. The cells were ana-
lyzed using an easyCyte 5-HT flow cytometer (Millipore
Guava Technologies, Hayward, USA). The data shown
are from two independent experiments.
Cell cycle analysis
After transfection and 14 days of selection with geneticin,
the cell cycle was synchronized by the removal of FBS,
and the cell cycle phases were assessed using the Cell
Cycle Immunofluorescence Kit (558662 - BD Biosciences,
San Diego, CA, USA). S phase cells were identified using
BrdU and AlexaFluor 488 Mouse anti-BrdU, M phase cells
were detected with an AlexaFluor 647 Rat anti-Histone
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H3 antibody (pS28) and G0/G1 phases were measured
with DAPI, according to the manufacturer’s instructions.
The cells were analyzed using an LSM 710 confocal
microscope (Zeiss, Germany).
RNA extraction and qRT-PCR
Total RNA was obtained using TRIzol reagent (Life
Technologies, Grand Island, NY) according to the manu-
facturer’s instructions. Approximately 5 μg of total RNA
from each sample were used to synthesize cDNA using
the High Capacity cDNA Kit (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s instruc-
tions. Real-Time PCR was performed using an ABI Prism
7300 Real Time PCR system and SYBR Green PCR Core
Reagent (Applied Biosystems, Warrington, UK) following
the manufacturer’s protocol. The primer sequences were
designed using Primer 3 software: E6 HPV16 – GACCCA
GAAAGTTACCACAG (Forward) and CATAAATCCCG
AAAAGCAAAG (Reverse); E7 HPV16 – ACAAGCAGA
ACCGGACAGAG (Forward) and TGCCCATTAACAGG
TCTTCC (Reverse); HTRA1 - CGCACTCATCAAAATT
GACC (Forward) and CTGTGTTTTGAAGGGAAAACG
(Reverse); GAPDH (endogenous control): ACCCACTCCT
Fig. 1 HTRA1 overexpression in HPV-positive (CasKi) and HPV-negative
(C33) cell lines. CasKi and C33 cells were transiently transfected with
pCMV6/Entry (empty vector) or pCMV6/HTRA1 and the overexpression of
HTRA1 was confirmed 48 h post-transfection by qRT-PCR. Quantitative
mRNA expression of the HTRA1 gene in both cell lines after transfection
with pCMV6/HTRA1 or the empty vector is shown as the fold change
(log2) relative to expression
Fig. 2 HTRA1 increases the proliferation and colony formation in CasKi cells and suppresses the same characteristics in the C33 cell line. Tumor
cell proliferation was assessed in vitro. Cells were transiently transfected with pCMV6/Entry (empty vector) or pCMV6/HTRA1 and replated 24 h
post-transfection for selection with Geneticin/G418. After 14 days of selection, the cells were replated. a Growth curve analysis showed that the
expression of HTRA1 increased cellular proliferation in CasKi cells and decreased cellular proliferation in C33 cells compared with that of the control
cells (CasKi and C33 cells transfected with empty vector). b A colony formation assay showed a marked reduction in the number of colonies in the C33
cells expressing HTRA1 and an increase in the number of colonies in CasKi cells expressing HTRA1 compared to the control cells
Stuqui et al. BMC Cancer  (2016) 16:840 Page 3 of 8
CCACCTTTGA (Forward) and CTGTTGCTGTAGCCA
AATTCGT (Reverse). In brief, the reaction mixture
(20 μL total volume) contained 25 ng of cDNA, gene-
specific forward and reverse primers for each gene, and
10 μL of 2x Quantitative SYBR Green PCR Master Mix.
The samples were tested in triplicate. The relative expres-
sion of each specific gene was calculated using the follow-
ing formula: R = (E target)ΔCt target (control - sample)/(E
endogenous)ΔCt endogenous (control - sample), which was pub-
lished previously [38]; a cutoff higher than a 2-fold change
was used.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5 Software. Functional comparisons between cells over-
expressing HTRA1 and cells with low HTRA1 expression
were performed using Student’s t test. In all analyses, the
differences were considered statistically significant when-
ever p < 0.05.
Results
HTRA1 overexpression in HPV-positive and HPV-negative
cell lines
After transfection with the pCMV6/HTRA1 expression
vector or with an empty vector (pCMV6/Entry), HTRA1
expression in the CasKi and C33 cell lines was accessed
using qRT-PCR. The HTRA1 gene was upregulated com-
pared to cells transfected with the empty vector in both
cell lines after transfection with the pCMV6/HTRA1
vector (***p < 0.001) (Fig. 1).
HTRA1 plays different roles in cell proliferation and
colony formation in CasKi and C33 cell lines
Cell proliferation and colony formation ability were
assessed after 14 days of selection of the transfected cells
with G418. Our results demonstrate that CasKi cells ex-
pressing HTRA1 had an increased proliferation rate
(Fig. 2a) and colonies density compared with the corre-
sponding control cells (Fig. 2b). However, in C33 cells
overexpressing HTRA1, a reduction in the cell growth
rate (Fig. 2a) and colony number was observed compared
to cells transfected with the empty vector (Fig. 2b).
The apoptosis rate is not influenced by HTRA1
The ability of HTRA1 to induce apoptosis was also eval-
uated. The rate of apoptosis was assessed using FITC-
Annexin V/PI after transfection with pCMV6/HTRA1
and selection with G418. No significant difference in
apoptosis was observed in both cell lines, whether over-
expressing or underexpressing HTRA1 (p > 0.05) (Fig. 3).
HTRA1 changes cell cycle progression
Cell cycle analysis on HPV-positive and HPV-negative cells
was performed using a cell cycle immunofluorescence assay
after transfection with pCMV6/HTRA1 and selection with
G418. There were more CasKi cells overexpressing HTRA1
in the S phase (***p < 0.001) and fewer cells overexpressing
HTRA1 in the G0/G1 phase after transfection (***p <
0.001) (Fig. 4a, b, c, g). The opposite was observed in the
C33 cell line, in which a higher number of cells overex-
pressing HTRA1 was observed in the G0/G1 phase (**p <
0.01) than in C33 cells transfected with the empty vector
(Fig. 4d, e, f, h).
Discussion
In this study, we analyzed the effects of HTRA1 overex-
pression in HPV-positive (CasKi) and HPV-negative
(C33) cell lines. Cervical carcinoma cells (C33) overex-
pressing HTRA1 had fewer colonies and a lower growth
rate than the control. Studies using MTT assays have
also reported that HTRA1 overexpression triggers a de-
crease in cell proliferation [22, 33], and colony numbers
were reduced in soft agar assays [33]. Different investiga-
tions observed the downregulation of HTRA1 expression
in various cancers types, such as melanoma, mesothelioma,
Fig. 3 Effect of HTRA1 on apoptosis. Apoptosis in the CasKi (a) and
C33 (b) cell lines was analyzed by flow cytometry after transfection
and 14 days of G418 selection. No difference in apoptosis was observed
in either cell line between cells overexpressing HTRA1 and those with
low HTRA1 expression levels (p > 0.05). Viable cells are located in the
bottom left (FITC-Annexin V negative/PI negative), early apoptotic cells
in the bottom right (FITC-Annexin V positive/PI negative), late apoptotic
or necrotic cells in the top right (FITC-Annexin V positive/PI positive)
and necrotic cells in the top left quadrants (FITC-Annexin V
negative/PI positive)
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lung, ovarian, bladder urothelial, breast, gallbladder and
gastric cancer [31, 32, 36, 39–43]. Exogenous HTRA1 ex-
pression induces apoptosis and a reduction of cell prolifera-
tion in transformed cells, suggesting a tumor suppressor
role for this protein [36, 44].
Xia et al. [45] showed a reduction in cell proliferation
and invasion in esophageal squamous cell carcinoma
overexpressing HTRA1 due to blockage of the nuclear
factor-κB signaling pathway coupled to a decrease in
the Ki-67, Bcl-2 (B-cell lymphoma 2), Bcl-xL (B-cell
lymphoma-extra large), cyclin D1 and MMP-9 (matrix
metalloproteinase 9) proteins. In endometrial cancer
cell lines, exogenous HTRA1 expression resulted in a
decrease in the invasive and migration potential of
these cells. Thereby, the loss of HTRA1 may contribute
to the aggressiveness and metastatic phenotype of cancer
cells [35].
In contrast to that observed in C33 cells, in the
HPV-16-positive cervical carcinoma cell line (CasKi)
HTRA1-overexpressing cells showed an increase in
colony formation and cell proliferation. This report is the
first to describe the effect of HTRA1 overexpression in
cells containing high-risk HPV. The increase in the colony
number and cell growth rate in HPV-positive HTRA1-
transfected cells could be explained by the viral replicative
cycle characteristics. These viruses express early proteins -
E6, E7 and E5 - that interact with cellular proteins and
interfere with normal cell cycle regulation. The E6 onco-
protein of high-risk HPVs is able to interact with the PDZ
domain of cellular proteins, preventing apoptosis and
stimulating the proliferation of infected cells [46, 47]. The
HTRA1 serine protease contains a PDZ domain in its
C-terminal region, and for this reason, it is a strong
candidate to interact with the E6 protein of high-risk
Fig. 4 Effect of HTRA1 on the cell cycle in cell lines. Cell cycle phases in CasKi and C33 cell lines were analyzed post-transfection and after 14 days
of G418 selection using an immunofluorescence assay. The number of CasKi cells in the S phase (green, AlexaFluor 488 Mouse anti-BrdU) and mitosis
(red, AlexaFluor 647 Rat anti-Histone H3) was increased, while the number of cells in G0/G1 phase (blue) significantly decreased for cells overexpressing
HTRA1 (b, g) compared with cells with low HTRA1 expression levels (a, g). The number of C33 cells overexpressing HTRA1 in G1/G0 was significantly
increased (blue, Hoechst) and the number of cells in S phase was decreased (green) (e, h) compared to C33 cells without HTRA1 expression
(d, h). c CasKi and f C33 cells incubated only with Hoechst were used as negative controls
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HPVs [25, 26], and the association of both proteins
may result in the bypass of growth arrest. In fact,
interaction between HTRA1 and HPV E6 proteins was
observed by Clawson et al. [48], however there are no
functional studies that describe the effects of this
association.
Some studies suggest that the interaction between the
E6 PBM (PDZ domain-binding motif ) and the PDZ do-
mains of cellular proteins increases E6 stability, promot-
ing high levels of E6 and HPV genome maintenance in
the cell [16, 17]. Nicolaides [16] showed that the inter-
action between E6 and the PDZ domain of two cellular
proteins involved in cell polarity, MAGI (Membrane As-
sociated Guanylate kinase Inverted) and hScrib (Scribble
Homolog Protein), increases E6 levels in immortalized
keratinocytes (NIKS), probably by preventing them from
proteasomal degradation. Furthermore, NIKS cells trans-
fected with an HPV 16 genome mutated in the E6
carboxy-terminal region presented low levels of E6, and
the viral genome was unable to remain as an epissome,
becoming degraded or integrated into the host genome.
For HPV 31, the loss of the E6 PBM domain was shown
to trigger reduction in the viral copy number in human
foreskin keratinocytes (HFK) [17].
We speculate that in CasKi cell line, E6 oncoprotein
could interact with HTRA1 PDZ domain, triggering high
levels of this viral oncoprotein in the cell and enhancing
E6 cellular transformation activity, prompting the prolif-
eration of HPV infected cells, which could explain the
increased cell proliferation observed in HPV-positive
cells overexpressing HTRA1.
The cell cycle was assessed in this study by immuno-
fluorescence to determine whether the changes in cellular
proliferation induced by HTRA1 overexpression could be
explained by modifications in the proportion of cells in
each cell cycle phase. In the HPV-negative cell line,
HTRA1 overexpression triggered cell cycle arrest, increas-
ing the number of cells in G0/G1 phase and reducing the
number of cells in synthesis (S) phase. In the HPV-
positive cell line, HTRA1 overexpression triggered cell
cycle progression by increasing the number of cells in S
phase and decreasing the number of cells in G0/G1. These
results are in agreement with the observed decrease in the
colony and cell numbers in C33 cells and increase in col-
ony and cell numbers in the CasKi cell line after HTRA1
overexpression. The data suggest a tumor suppressor role
only in HPV-negative cells (C33 cells) and an opposite ef-
fect in HPV-positive cells (CasKi cells).
One limitation of our study is that due to the different
genetic background of the transformed C33 and CasKi
cell lines, our experiments do not allow us to infer the
mechanism by which HTRA1 overexpression reduced
proliferation only in the HPV-negative cell line. How-
ever, it is possible that the interaction between E6 and
HTRA1 showed by immunoprecipitation [48] depends
on the PDZ domain and triggers a high level of E6 onco-
protein in the cell, enhancing its cellular transformation
activity. However, other studies are necessary to investi-
gate how HTRA1 increases cell proliferation in the
CasKi cell line and in other HPV-positive cell lines and
tumors.
Conclusions
HTRA1 overexpression prevents cell proliferation in the
HPV-negative cell line, as described in the literature in
other tumor cells, via cell cycle arrest in G0/G1. On the
other hand, HTRA1 increases cell proliferation in the
HPV-positive cell line, inducing cell cycle progression by
increasing the number of cells in S phase and decreasing
the number of cells in G0/G1. However, more studies
are required to determine whether this high rate of cel-
lular proliferation is a result of the E6/HTRA1 PDZ
interaction.
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